Daftar Pustaka.docx

DAFTAR PUSTAKA

1. Ferlay JSI, Ervik M, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5) 2. ....... . Buku ajar onkologi klinik. Balai Penerbit FKUI. 2008; ...................... 3. Nutt M, Reed Z, Köhler TS. Vasectomy and prostate cancer risk: a historical synopsis of undulating false causality. Res Rep Urol. 2016; 8: 85–93. 4. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012; 60(1): 199–215. 5. Boyle P, Brawley OW. Prostate cancer: current evidence weighs against population screening CA Cancer J Clin. 2009 Juli 1; 59(4): 220-4. 6. Mittakanti HR, Thomas IC, Shelton JB, et al. Accuracy of prostate-specific antigen values in prostate cancer registries. J Clin Oncol. 2016 Juli 25. 7. Kwon OJ, Zhang B, Zhang L, Xin L. High fat diet promotes prostatic basal-to-luminal differentiation and accelerates initiation of prostate epithelial hyperplasia originated from basal cells. Stem Cell Res. Mei 2016; 16(3): 682-91. Available from : http://www.cdc.gov/cancer/prostate/statistics/race.htm 8. Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-walsh urology. 11th ed. Philadelphia: ELSEVIER; 2016 9. B 10. Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003 11. Mortimer D. Practical laboratory andrology. New York: Oxford University Press; 1994: 23 12. Sherwood, L. Fisiologi manusia; dari sel ke sistem. 2nd ed. Jakarta: EGC; 2013. p. 797-8 13. Mescher AL. Junquiera’s basic histology text and atlas. 3rd ed. Indiana: Mc Graw Hill; 2013. p. 442-4 14. Dorland, W. A. Newman. Dorland's Illustrated Medical Dictionary. 1st ed. Philadelphia, PA: Saunders; 2007. 15. National Cancer Institute. Prostate cancer. National Institutes of Health. 2014 Oktober. Available from: https://www.cancer.gov/types/prostate .

16. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003; 349 (4): 36681. 17. Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology. 2012; 60: 4. 18. David GB, Lina L, Michael KB, Junqi Q. High-grade prostatic intraepithelial neoplasia. Rev Urol. 2004; 6(4): 171–179. 19. Cheville JC, Reznicek MJ, Bostwick DG. The focus of atypical glands, suspicious for malignancy in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol. 1997 Dec; 108(6):633-40. 20. Peter AH et al. High grade prostatic intraepithelial neoplasia in prostate needle biopsy. J Urol. 2013 Jan;189(1):315-6. 21. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology. 2006; 68: 1263–7. 22. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009; 55: 310–32. 23. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005; 97: 103–15. 24. Jerónimo C, Bastian PJ, Bjartell A, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011; 60: 753–66. 25. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005; 97: 103–15. 26. Yang L, Lin C, Jin C, et al. lncRNA-dependent mechanisms of androgenreceptor-regulated gene activation programs. Nature. 2013b; 500: 598–602. 27. van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol. 2007; 52: 455–63. 28. Garzon R, Calin GA, Croce CM, et al. MicroRNAs in cancer. Annu Rev Med. 2009; 60: 167–79. 29. Catto JWF, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011; 59: 671–81

30. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69: 532–5. 31. Chung S, Nakagawa H, Uemura M, et al. Association of a novel long noncoding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011; 102: 245–52. 32. Yang L, Lin C, Jin C, et al. lncRNA-dependent mechanisms of androgenreceptor-regulated gene activation programs. Nature 2013; 500: 598–602. 33. Holzbeierlein J, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 2004; 164: 217–227 34. Levesque MH, El-Alfy M, Berger L, Labrie F, Labrie C. Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases. Urology. 2007 Jan; 69(1): 196-201. 35. Schmidt U, Fuessel S, Koch R, Baretton GB, et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate. 2006 Oct 1;66(14):1521-34. 36. Cui X, Cui M, Asada R, et al. The androgen-induced protein AIbZIP facilitates proliferation of prostate cancer cells through downregulation of p21 expression. Sci Rep. 2016 Nov 17; 6: 37310. 37. Barbieri CE, Tomlins SA. The prostate cancer genome: perspectives and potential. Urol Oncol. 2014;32:53, e15–22 38. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644–8. 39. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013; 153: 666–77. 40. Schrecengost RS, Knudsen KE. Molecular Pathogenesis and Progression of Prostate Cancer. Seminars in oncology. 2013;40(3):244-258. 41. Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature genetics. 2012;44:685–689. 42. Williams N, Hughes LJ, Turner EL, et al. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities (link is external). BJU Int 2011;108(9):1402-8. Available from: http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#ref-1 .

43. Choudhury AD, Eeles R, Freedland SJ, et al. The role of genetic markers in the management of prostate choancer. Eur Urol 2012;62:577–87. 44. Eeles R, Goh C, Castro E, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 2014;11:18–31. 45. Castillejos-Molina RA, Gabilondo-Navarro FB. Prostate cancer. Salud Publica Mex. 2016 Apr;58(2):279-84. 46. American Cancer Society. Prostate cancer. Atlanta: American Cancer Society; 2016. 47. Ji J, Sundquist J, Sundquist K. Association of family history of type 2 diabetes with prostate cancer: a national cohort study. Front Oncol. 2016 Aug 29;6:194. 48. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607–15. 49. Sfanos KS, Isaacs WB, De Marzo AM. Infection and inflammation in prostate cancer. Am J Clin Exp Urol. 2013; 1(1): 3–11. 50. Dwivedi S, Goel A, Mandhani A, Khattri S, Pant KK. Tobacco exposure may enhance inflammation in prostate carcinoma patients: an explorative study in north Indian population. Toxicol Int. 2012 Sep;19(3):310-8. 51. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur. Urol. 2014; 66: 1054–1064. 52. Moreira DM, Aronson WJ, Terris MK, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer 2014;120:197–204. 53. Freedland SJ, Platz EA, Presti JC Jr, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006;175:500–4. 54. Buschemeyer WC 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331–43. 55. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur. Urol. 2013; 63: 800–9. 56. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995;41:54–8.

57. Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al. Human kallikrein 2 (hK2) and prostatespecific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275–368. 58. Végvári A, Rezeli M, Welinder C, et al. Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. J Proteomics 2010;73:1137–47. 59. Peyromaure M, Fulla Y, Debré B, Dinh-Xuan AT. Pro psa : a "pro cancer" form of psa?. Med Hypotheses. 2005;64(1):92-5. 60. Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P, Huland H, Lilja H. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol. 2002 Nov; 168(5): 1917-22. 61. American Cancer Society. Prostate cancer overview. Prostate Cancer. Atlanta, GA: American Cancer Society; 2011 May 4. Retrieved from: http://www.cancer.org/. 62. Humphrey PA, Srigley JR, Amin MB, et al. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. College of American Pathologists. Northfield, IL: College of American Pathologists; Oktober 2019. Retrieved from: http://www.cap.org/apps/cap.portal. 63. National Clinical Guideline Centre (UK). The Management of Lower Urinary Tract Symptoms in Men [Internet]. London: Royal College of Physicians (UK); 2010. (NICE Clinical Guidelines, No. 97.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK65073/ 64. Perera M, Lawrentschuk N, Perera N, Bolton D, Clouston D. Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years. Prostate International. 2016;4(1):11-14. 65. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 1992;23:258-66. 66. Merrill RM, Wiggins CL. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 2002;7:213-9. 67. Srigley JR, Humphrey PA, Amin MB, et al. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 2009;133:1568-76.